Morphotek’s Busy Year Continues With NCI Collaboration On Prostate Cancer Antibody
This article was originally published in The Pink Sheet Daily
Executive Summary
Company hopes monoclonal antibody identified by NCI will demonstrate utility in multiple cancer types.
You may also be interested in...
Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition
Japanese firm plans to grow U.S. sales to $4 billion via expanded sales force of 1,500 by 2011, Eisai tells “The Pink Sheet” DAILY.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.